Oppenheimer Initiates Coverage On TriSalus Life Sciences with Outperform Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with an Outperform rating and set a price target of $10.

September 16, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on TriSalus Life Sciences with an Outperform rating and a price target of $10, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $10 by a reputable analyst like Oppenheimer is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100